Galena Biopharma has entered into an agreement with Orexo AB to acquire Abstral (fentanyl) Sublingual Tablets for sale and distribution in the U.S. Galena will pay $10 million upfront and $5 million in the first 12 months of closing, plus royalties and milestones based on sales.   Abstral is a new treatment option for inadequately controlled breakthrough cancer pain (BTcP) in patients who are receiving, and tolerant to, opioid therapy for cancer pain. The Abstral formulation delivers the analges...